Will the Novo-Catalent merger be challenged under the new Trump administration? A former FTC policy director thinks so.

Charles Schwab Investment Management Inc. boosted its stake in Catalent, Inc. (NYSE:CTLT – Free Report) by 1.1% during the ...

Adds Reuters report. Catalent (NYSE:CTLT) rose 2.2% amid reports that the European Union's antitrust regulator will likely ...

Pharma leaders hoping for a friendlier merger environment after the Trump administration grabs the keys to the White House ...

Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug ...

Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is slated to received unconditional EU antitrust approval for its proposed ...

The growing inclination for biologics and biosimilars is driving the sterile injectable contract manufacturing market.New ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent , people familiar with the ...

Catalent (NYSE:CTLT) rose 2% amid a report that the European Union's antitrust regulator will likely grant approval for its ...

(Reuters) - Contract drug manufacturer Catalent, which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

Catalent, Inc. CTLT reported first-quarter fiscal 2025 adjusted loss per share of 13 cents, flat year over year. The figure was wider than the Zacks Consensus Estimate of a loss of 11 cents per share.

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer ...